The Institute of Ophthalmology was officially opened in November 1948 as an ophthalmology training facility specialised in fundamental research [REF].
In September 2010 the Institute entered into a three-year agreement with the pharmaceutical company AstraZeneca to collaborate on the identification of new treatments for diabetic retinopathy using the regenerative capacity of stem cells [REF].